Have a feature idea you'd love to see implemented?
Let us know!
RXRX Recursion Pharmaceuticals Inc
Price (delayed)
$6.32
Market cap
$1.81B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.55
Enterprise value
$1.47B
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients
Highlights
Recursion Pharmaceuticals's gross profit has soared by 169% from the previous quarter
The gross margin has surged by 105% since the previous quarter
RXRX's equity is up by 20% year-on-year but it is down by 10% since the previous quarter
The company's EPS fell by 7% YoY but it rose by 5% QoQ
The debt has surged by 76% year-on-year
Recursion Pharmaceuticals's net income has decreased by 29% YoY
Key stats
What are the main financial stats of RXRX
Market
Valuations
Earnings
Shares outstanding
286.64M
Market cap
$1.81B
Enterprise value
$1.47B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.39
Price to sales (P/S)
27.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.6
Revenue
$65.18M
Gross profit
$22.86M
Net income
-$377.75M
EBIT
-$382.95M
EBITDA
-$338.65M
Free cash flow
-$332.29M
Per share
Balance sheet
Liquidity
EPS
-$1.55
EPS diluted
-$1.55
Free cash flow per share
-$1.18
Book value per share
$1.87
Revenue per share
$0.23
TBVPS
$2.27
Total assets
$726.5M
Total liabilities
$201.94M
Debt
$90.63M
Equity
$524.56M
Working capital
$365.28M
Debt to equity
0.17
Current ratio
4.35
Quick ratio
3.96
Net debt/EBITDA
1
Margins
Efficiency
Dividend
EBITDA margin
-519.5%
Gross margin
35.1%
Net margin
-579.5%
Operating margin
-604.7%
Return on assets
-55.7%
Return on equity
-76.6%
Return on invested capital
-223.8%
Return on capital employed
-62%
Return on sales
-587.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RXRX stock price
How has the Recursion Pharmaceuticals stock price performed over time
Intraday
-6.23%
1 week
-15.62%
1 month
-9.06%
1 year
-43.37%
YTD
-6.51%
QTD
-6.51%
Financial performance
How have Recursion Pharmaceuticals's revenue and profit performed over time
Revenue
$65.18M
Gross profit
$22.86M
Operating income
-$394.17M
Net income
-$377.75M
Gross margin
35.1%
Net margin
-579.5%
Recursion Pharmaceuticals's gross profit has soared by 169% from the previous quarter
The gross margin has surged by 105% since the previous quarter
RXRX's revenue is up by 38% year-on-year and by 31% since the previous quarter
Recursion Pharmaceuticals's net income has decreased by 29% YoY
Growth
What is Recursion Pharmaceuticals's growth rate over time
Valuation
What is Recursion Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.39
P/S
27.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.6
The company's EPS fell by 7% YoY but it rose by 5% QoQ
RXRX's price to book (P/B) is 21% lower than its last 4 quarters average of 4.3
RXRX's equity is up by 20% year-on-year but it is down by 10% since the previous quarter
RXRX's revenue is up by 38% year-on-year and by 31% since the previous quarter
RXRX's price to sales (P/S) is 32% lower than its last 4 quarters average of 40.5
Efficiency
How efficient is Recursion Pharmaceuticals business performance
Recursion Pharmaceuticals's return on assets has decreased by 25% YoY but it has increased by 2.8% QoQ
The company's return on sales rose by 23% QoQ and by 4.9% YoY
RXRX's ROIC is up by 22% YoY and by 12% QoQ
Recursion Pharmaceuticals's return on equity has decreased by 19% YoY but it has increased by 3.6% QoQ
Dividends
What is RXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RXRX.
Financial health
How did Recursion Pharmaceuticals financials performed over time
The quick ratio has declined by 29% since the previous quarter and by 5% year-on-year
The company's current ratio fell by 28% QoQ
The debt is 83% smaller than the equity
The debt has surged by 76% year-on-year
RXRX's debt to equity is up by 42% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.